            <table>
                <thead>
                    <tr>
                        <th>Microorganism<span aria-hidden="true" style="display: none;">
                                . </span></th>
                        <th>Preferred Treatment<sup>a</sup><span aria-hidden="true" style="display: none;">
                                . </span></th>
                        <th>Alternative Treatment<sup>a</sup><span aria-hidden="true" style="display: none;">
                                . </span></th>
                        <th>Comments<span aria-hidden="true" style="display: none;">
                                . </span></th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td rowspan="5">Staphylococci, oxacillin-susceptible </td>
                        <td>Nafcillin<sup>b</sup> sodium 1.5–2 g IV q4-6 h </td>
                        <td>Vancomycin IV 15 mg/kg q12 h </td>
                        <td rowspan="5">See recommended use of rifampin as a companion drug for rifampin-susceptible PJI
                            treated with debridement and retention or 1-stage exchange in text </td>
                    </tr>
                    <tr>
                        <td>or </td>
                        <td>or </td>
                    </tr>
                    <tr>
                        <td>Cefazolin 1–2 g IV q8 h </td>
                        <td>Daptomycin 6 mg/kg IV q 24 h </td>
                    </tr>
                    <tr>
                        <td>or </td>
                        <td>or </td>
                    </tr>
                    <tr>
                        <td>Ceftriaxone<sup>c</sup> 1–2 g IV q24 h </td>
                        <td>Linezolid 600 mg PO/IV every 12 h </td>
                    </tr>
                    <tr>
                        <td>Staphylococci, oxacillin-resistant </td>
                        <td>Vancomycin<sup>d</sup> IV 15 mg/kg q12 h </td>
                        <td>Daptomycin 6 mg/kg IV q24 horLinezolid 600 mg PO/IV q12 h </td>
                        <td>See recommended use of rifampin as a companion drug for rifampin-susceptible PJI treated
                            with debridement and retention or 1-stage exchange in text </td>
                    </tr>
                    <tr>
                        <td><em>Enterococcus</em> spp, penicillin-susceptible </td>
                        <td>Penicillin G 20–24 million units IV q24 h continuously or in 6 divided doses
                            <br />or<br />Ampicillin sodium 12 g IV q24 h continuously or in 6 divided doses </td>
                        <td>Vancomycin 15 mg/kg IV q12 h <br /><br />or <br />Daptomycin 6 mg/kg IV q24 h </td>
                        <td>4–6 wk. Aminoglycoside optional <br /><br />Vancomycin should be used only in case of
                            penicillin allergy </td>
                    </tr>
                    <tr>
                        <td> </td>
                        <td> </td>
                        <td>or </td>
                        <td> </td>
                    </tr>
                    <tr>
                        <td> </td>
                        <td> </td>
                        <td>Linezolid 600 mg PO or <br /> IV q12 h </td>
                        <td> </td>
                    </tr>
                    <tr>
                        <td><em>Enterococcus</em> spp, penicillin-resistant </td>
                        <td>Vancomycin 15 mg/kg IV q12 h </td>
                        <td>Linezolid 600 mg PO or <br /><br />IV q12 h <br /><br />or <br />Daptomycin 6 mg IV q24 h 
                        </td>
                        <td>4–6 wk. Addition of aminoglycoside optional </td>
                    </tr>
                    <tr>
                        <td><em>Pseudomonas aeruginosa</em> </td>
                        <td>Cefepime 2 g IV q12 h </td>
                        <td>Ciprofloxacin 750 mg PO bid </td>
                        <td>4–6 wk </td>
                    </tr>
                    <tr>
                        <td> </td>
                        <td>or </td>
                        <td>or 400 mg IV q12 h </td>
                        <td>Addition of aminoglycoside optional </td>
                    </tr>
                    <tr>
                        <td> </td>
                        <td>Meropenem<sup>e</sup> 1 g IV q8 h </td>
                        <td>or </td>
                        <td rowspan="2">Use of 2 active drugs could be considered based on clinical circumstance of
                            patient. If aminoglycoside in spacer, and organism aminoglycoside susceptible than double
                            coverage being provided with recommended IV or oral monotherapy </td>
                    </tr>
                    <tr>
                        <td> </td>
                        <td> </td>
                        <td>Ceftazidime 2 g IV q8 h </td>
                    </tr>
                    <tr>
                        <td><em>Enterobacter</em> spp </td>
                        <td>Cefepime 2 g IV q12 h <br />or <br />Ertapenem 1 g IV q24 h </td>
                        <td>Ciprofloxacin 750 mg PO <br /> or 400 mg IV q12 h </td>
                        <td>4–6 wk. </td>
                    </tr>
                    <tr>
                        <td>Enterobacteriaceae </td>
                        <td>IV β-lactam based on in vitro susceptibilities or <br />Ciprofloxacin 750 mg PO bid </td>
                        <td> </td>
                        <td>4–6 wk </td>
                    </tr>
                    <tr>
                        <td>β-hemolytic streptococci </td>
                        <td>Penicillin G 20–24 million units IV q24 h continuously or in 6 divided doses <br />or
                            <br />Ceftriaxone 2 g IV q24 h </td>
                        <td>Vancomycin 15 mg/kg IV q12 h </td>
                        <td>4–6 wk <br />Vancomycin only in case of allergy </td>
                    </tr>
                    <tr>
                        <td><em>Propionibacterium acnes</em> </td>
                        <td>Penicillin G 20 million units IV q24 h continuously or in 6 divided doses <br />or
                            <br />Ceftriaxone 2 g IV q24 h </td>
                        <td>Clindamycin 600–900 mg IV q8 h or clindamycin 300–450 mg PO qid <br />or <br />Vancomycin
                            15 mg/kg IV q12 h </td>
                        <td>4–6 wk <br /><br />Vancomycin only in case of allergy </td>
                    </tr>
                </tbody>
            </table>
                    <p class="chapter-para">Abbreviations: bid, twice daily; IV, intravenous; PJI, prosthetic joint
                        infection; q, every; PO, per oral; qid, 4 times daily.</p>
                    <p class="chapter-para"><sup>a</sup> Antimicrobial dosage needs to be adjusted based on patients'
                        renal and hepatic function. Antimicrobials should be chosen based on in vitro susceptibility as
                        well as patient drug allergies, intolerances, and potential drug interactions or
                        contraindications to a specific antimicrobial. Clinical and laboratory monitoring for efficacy
                        and safety should occur based on prior IDSA guidelines [6]. The possibility of prolonged QTc
                        interval and tendinopathy should be discussed and monitored when using fluoroquinolones. The
                        possibility of <em>Clostridium difficile</em> colitis should also be discussed when using any
                        antimicrobial.</p>
                    <p class="chapter-para"><sup>b</sup> Flucloxacillin may be used in Europe. Oxacillin can also be
                        substituted.</p>
                    <p class="chapter-para"><sup>c</sup> There was not a consensus on the use of ceftriaxone for
                        methicillin-susceptible staphylococci (see text).</p>
                    <p class="chapter-para"><sup>d</sup> Target troughs for vancomycin should be chosen with the
                        guidance of a local infectious disease physician based on the pathogen, its in vitro
                        susceptibility, and the use of rifampin or local vancomycin therapy. Recent guidelines [<span
                            class="xrefLink" id="jumplink-CIS803C155"></span>155, <span class="xrefLink"
                            id="jumplink-CIS803C164"></span>164] for the treatment of methicillin-resistant
                        <em>Staphylococcus aureus</em> (MRSA) infections have been published. (These guidelines suggest
                        that dosing of vancomycin be considered to achieve a vancomycin trough at steady state of 15 to
                        20. Although this may be appropriate for MRSA PJI treated without rifampin or without the use of
                        local vancomycin spacer, it is unknown if these higher trough concentrations are necessary when
                        rifampin or vancomcyin impregnated spacers are utilized. Trough concentrations of at least 10
                        may be appropriate in this situation. It is also unknown if treatment of oxacillin-resistant,
                        coagulase-negative staphylococci require vancomycin dosing to achieve these higher vancomycin
                        levels.)</p>
                    <p class="chapter-para"><sup>e</sup> Other antipseudomonal carbapenems can be utilized as well.</p>